 |
217 Diseases |  |
228 Trials |
|
228 Trials |  |
3892 News |  |
| «12...1920212223242526272829...4950» |
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
Clinical, Journal, BRCA Biomarker, PARP Biomarker: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). (Pubmed Central) - Jan 21, 2021
P2
GeparOLA could not exclude a pCR rate of ≤55% in the PO arm. PO was significantly better tolerated and the combination merits further evaluation.
- || epirubicin / Generic mfg.
Clinical, Journal: Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. (Pubmed Central) - Jan 20, 2021
PO was significantly better tolerated and the combination merits further evaluation. Compared to cTACE alone, DEB-TACE combined with cTACE significantly increased the ORR at 1 and 3 months after the treatment of unresectable large HCCs, and had a longer TTP, without any significant increase in the number of severe complications.
- capecitabine / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial () - Jan 17, 2021 - Abstract #YIR2021YIR_131;
- | oxaliplatin / Generic mfg.
Journal: Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. (Pubmed Central) - Jan 16, 2021
Compared to cTACE alone, DEB-TACE combined with cTACE significantly increased the ORR at 1 and 3 months after the treatment of unresectable large HCCs, and had a longer TTP, without any significant increase in the number of severe complications. HAIC may significantly improve OS and provide better tumor control with mild side effects and preserved liver function in patients with advanced HCC with major PVTT compared to TACE/TAE treatment.
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Changes in the levels of T lymphocytes and inflammatory factors in the peripheral blood of breast cancer patients during postoperative chemotherapy. (Pubmed Central) - Jan 16, 2021
Dynamic monitoring of changes in the levels of T lymphocytes and inflammatory factors during chemotherapy may be of clinical value for predicting the risk of infection. Implementing targeted intervention measures for these risk factors may therefore be beneficial for controlling infection.
- | epirubicin / Generic mfg.
Journal: Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells. (Pubmed Central) - Jan 15, 2021
In vivo treatment with both PEG-HAp and FA-PEG-HAp nanoparticles had notably higher inhibition efficacy towards tumor growth than free epirubicin. In conclusion, folate conjugation provided higher uptake and better targeting of hydroxyapatite nanoparticles to cancer cells.
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Left atrial function assessed by speckle tracking echocardiography in anthracycline-induced cardiotoxicity: a case report. (Pubmed Central) - Jan 15, 2021
This is a case report suggesting that LA reservoir function might be a more sensitive indicator than LVEF or LV-GLS in detecting CTRCD and that LA booster function might be the earliest. Left atrium reservoir function might be a more sensitive than conventional LV pump function and optimal indicator in CTRCD.
- || Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Clinical, Journal: Successful treatment of G-CSF-related aortitis with prednisolone during preoperative chemotherapy for breast cancer: a case report. (Pubmed Central) - Jan 15, 2021
We successfully treated PEG-G-induced aortitis using prednisolone. Although this side effect is rare, cancer patients receiving PEG-G for chemotherapy should be monitored for aortic inflammation.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin. (Pubmed Central) - Jan 14, 2021
The TACL-ECF treatment was better tolerated than sorafenib. The TACL-ECF might be considered as an alternative therapy for the patients with TACE-DOX refractoriness, especially CPC B and sorafenib-intolerant patients.
- ||| gemcitabine / Generic mfg.
Clinical, P3 data, Journal: Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. (Pubmed Central) - Jan 14, 2021
P, P=N/A,
The TACL-ECF might be considered as an alternative therapy for the patients with TACE-DOX refractoriness, especially CPC B and sorafenib-intolerant patients. Adding gemcitabine to a standard chemotherapy does not improve the outcomes in patients with high-risk early breast cancer and should therefore not be included in the adjuvant treatment setting.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume. (Pubmed Central) - Jan 13, 2021
The findings point to the significance of cell loss for tumour growth rate. The metric should be considered in personalized oncology and in the evaluation of new therapeutic modalities.
- || P2 data, Journal: Phase II Study of Preoperative Intra-Arterial Epirubicin, Etoposide, and Oxaliplatin Combined with Oral S-1 Chemotherapy for the Treatment of Borrmann Type 4 Gastric Cancer. (Pubmed Central) - Jan 12, 2021
P2
Based on these preliminary data, a phase III study will be conducted to confirm the superiority of this regimen over standard treatment. ClinicalTrials.gov Identifier: NCT02949258.
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal, HEOR: Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. (Pubmed Central) - Jan 9, 2021
P3
ClinicalTrials.gov Identifier: NCT02949258. Negative HRQoL impact of the dose-dense and tailored strategy appears to be prominent during treatment, but HRQoL recover once treatment ends.
- || irinotecan / Generic mfg.
Biomarker, Clinical, Journal, Tumor Mutational Burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in cancer patients. (Pubmed Central) - Jan 9, 2021
The potential for immunotherapy and taxane (TUBB3 negativity) combinations is present for MSI-H but not TMB-H or PD-L1-expressing tumors; for temozolomide and dacarbazine (MGMT negative), PD-L1 is frequently co-expressed, but MSI-H and TMB-H are not associated. Protein markers of potential chemotherapy response along with NGS for immunotherapy response markers can help support rational combinations as part of an individualized, precision oncology approach.
- | epirubicin / Generic mfg.
Biomarker, Journal, Next-generation sequencing, Tumor Mutational Burden: Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing. (Pubmed Central) - Jan 8, 2021
BCG instillation significantly reduced the rate of recurrence compared with epirubicin in this population. Potential biomarkers and therapeutic targets were found with the help of next-generation sequencing; correlations between DDR genes alterations and high tumor mutation burden were also demonstrated.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: A Case of Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi. (Pubmed Central) - Jan 6, 2021
We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.
- | Enrollment closed, Enrollment change: NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) (clinicaltrials.gov) - Jan 6, 2021
P3, N=377, Active, not recruiting, Sponsor: Cancer Trials Ireland
This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies. Recruiting --> Active, not recruiting | N=540 --> 377
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Study on Regorafenib Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma after First Line Targeted Therapy () - Jan 6, 2021 - Abstract #DLCS2021DLCS_50;
The 3 and 6 month progression free survival rate (PFSR) was 92.7%. and 81.3% respectively.
- || paclitaxel / Generic mfg.
Clinical, Journal, BRCA Biomarker: Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. (Pubmed Central) - Jan 6, 2021
P3
Patients with triple-negative BC (TNBC) randomized to the PM arm received additional carboplatin (PMCb)...The elevated pCR rate in BRCA1/2-mutated ERBB2-negative, hormone receptor-positive BC suggests that germline BRCA1/2 testing should be considered prior to treatment start. ClinicalTrials.gov Identifier: NCT02125344.
- | AS1411 / Antisoma, Qualigen Therap, University of Louisville
Journal: High payload and targeted release of anthracyclines by aptamer-tethered DNA nanotrains - Thermodynamic and release kinetic study. (Pubmed Central) - Jan 6, 2021
These findings revealed that AS1411NTrs had high payload and targeted release capacity for DOX, EPI, and DAU. This result can provide a theoretical basis for constructing reasonable DNA nanostructures based on drug carriers.
- || carboplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. (Pubmed Central) - Jan 6, 2021
This result can provide a theoretical basis for constructing reasonable DNA nanostructures based on drug carriers. This study indicates that carboplatin plus taxanes could be a feasible adjuvant chemotherapy for patients with early TNBC who are cannot tolerate intensive chemotherapy with anthracycline.
- | Journal: Multicomponent synthesis, binding mode and structure-activity relationships of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups. (Pubmed Central) - Jan 5, 2021
Furthermore, a combinatorial high throughput drug screen revealed significantly enhanced cytotoxicity when NR-160 was used in combination with epirubicin and daunorubicin. The synergistic effect in combination with bortezomib and anthracyclines highlights NR-160´s potential in combination therapies.
- || dexamethasone / Generic mfg., vinorelbine tartrate / Generic mfg.
Clinical, Journal: Cutaneous plaque in adult T cell leukemia/lymphoma: A case report. (Pubmed Central) - Jan 5, 2021
Patch and plaque ATLL types exhibits a better survival rate, but atypical skin patches delays the diagnosis of ATLL and negatively affects the patient survival. Based on the present findings, we suggest that patients with petal-like nuclear lymphocytes in blood smears, a high CD4: CD8 ratio, and strong CD25 expression should undergo HTLV-1 serology testing.
- Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] Experiences of providing commercial Chimeric Antigen Receptor (CAR‐T) cell therapy at the Northern Centre for Cancer Care () - Jan 5, 2021 - Abstract #BSHI2020BSH-I_19;
Six (40%) received steroids (in all cases this was IV dexamethasone) for issues related directly to CAR‐T therapy...Four patients (29% of cohort available to follow‐up) have died after CAR‐T infusion. Progression‐free survival rates as calculated at standardised follow‐up points were 71% at 28 days, 31% at 3 months, and 27% at 6 months after CAR‐T infusion. One patient who had initial disease progression later had a subsequent complete response after receiving another line of treatment.
- ||| cyclophosphamide intravenous / Generic mfg.
Clinical, P3 data, Journal: High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. (Pubmed Central) - Dec 30, 2020
P3
High-dose chemotherapy did not affect long-term risk of a second malignant neoplasm or major cardiovascular events. ClinicalTrials.gov Identifier: NCT03087409.
- | zoledronic acid / Generic mfg., epirubicin / Generic mfg., gemcitabine / Generic mfg.
Journal: A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma. (Pubmed Central) - Dec 30, 2020
Moreover, the nanoparticle was loaded with multiple anti-cancer drugs like gemcitabine and epirubicin...The increased cytotoxicity and increased cellular uptake may be of greater advantage in systemic osteosarcoma therapy. Combining all results, our study demonstrated substantial potential towards management of osteosarcoma.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Metastases: Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 30, 2020
P2, N=60, Recruiting, Sponsor: Henan Cancer Hospital
Combining all results, our study demonstrated substantial potential towards management of osteosarcoma. Trial completion date: Jun 2022 --> Jun 2024
- | Brukinsa (zanubrutinib) / BeiGene
Enrollment open: Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Dec 29, 2020
P2, N=59, Recruiting, Sponsor: Henan Cancer Hospital
Trial completion date: Jun 2022 --> Jun 2024 Not yet recruiting --> Recruiting
- | Review, Journal: Metabolic and Non-Metabolic Pathways that Control Cancer Resistance to Anthracyclines. (Pubmed Central) - Dec 23, 2020
Resistance to anthracyclines is associated to the acquisition of multidrug resistance conferred by overexpression of permeability glycoprotein-1 or other efflux pumps, by altered DNA repair, changes in topoisomerase II activity, cancer stemness and metabolic adaptations. This review further details the metabolic aspects of resistance to anthracyclines, emphasizing the contributions of glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, glutathione, lipid metabolism and autophagy to the chemoresistant phenotype.
- || Herceptin (trastuzumab) / Roche
Clinical, Journal: Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. (Pubmed Central) - Dec 23, 2020
P3
This review further details the metabolic aspects of resistance to anthracyclines, emphasizing the contributions of glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, glutathione, lipid metabolism and autophagy to the chemoresistant phenotype. Dual HER2 blockade with T + L is a safe regimen from a cardiac perspective, but cardiac-focused history for proper patient selection is crucial.
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov) - Dec 23, 2020
P2, N=366, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Dual HER2 blockade with T + L is a safe regimen from a cardiac perspective, but cardiac-focused history for proper patient selection is crucial. Trial completion date: Jun 2031 --> Jun 2032 | Trial primary completion date: Jun 2024 --> Jun 2025
- || paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer. (Pubmed Central) - Dec 21, 2020
HRD-high tumors were associated with aggressive phenotypes and gHRRm, but not sHRRm. Our findings suggested that HRD scores might be useful in predicting response to P-FEC in the luminal subtype.
- || AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Dec 20, 2020
P2, N=20, Recruiting, Sponsor: Shandong Cancer Hospital and Institute
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P3 data, Journal: Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. (Pubmed Central) - Dec 20, 2020
P3
The PEONY trial adds to the totality of data showing the benefit of the pertuzumab regimen. ClinicalTrials.gov identifier: NCT02586025.
- || epirubicin / Generic mfg.
That reminds me of when I had epirubicin through a PICC line in my chest https://t.co/wYscaqHd63 (Twitter) - Dec 19, 2020
- | epirubicin / Generic mfg.
Journal: The Predictive Value of 2D Myocardial Strain for Epirubicin-Induced Cardiotoxicity. (Pubmed Central) - Dec 19, 2020
Patients whose GLS remained decreased after 3 months from anthracyclines-base chemotherapy had an increased risk for developing subsequent CTRCD. Further studies with larger sample size are warranted to identify the best cardioprotective molecules to be initiated in these patients before LVEF declines.
- || cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. (Pubmed Central) - Dec 18, 2020
In conclusion, a higher RDI of chemotherapy is associated with better survival but with a higher probability of causing adverse events. To optimize survival benefits, the RDI should be maintained ≥ 85% for HR(+) patients and ≥ 80% for HR(-) patients.
- || epirubicin / Generic mfg.
Clinical, Observational data, Journal: Identifying Risk Factors for Anthracycline Chemotherapy-induced Phlebitis in Women with Breast Cancer: An Observational Study. (Pubmed Central) - Dec 17, 2020
It is recommended that a CVC is not routinely required for women with breast cancer who have not undergone an axillary node clearance and receive chemotherapy in alternate arms. The need for a CVC for women who are planned to receive all anthracycline chemotherapy cycles in the same arm should be assessed in the light of peripheral venous access assessment and the key risk factors of age, dose and number of cycles.
- || oxaliplatin / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. (Pubmed Central) - Dec 17, 2020
Expression or activity of class 1 HDACs among gastric cancer patients present an effective approach for patient stratification. Furthermore, HDACi therapy in pre-treatment regimes is more effective with chemotherapy drugs, and may aid in predicting individual patient prognosis.
- || carboplatin / Generic mfg., paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. (Pubmed Central) - Dec 17, 2020
Furthermore, HDACi therapy in pre-treatment regimes is more effective with chemotherapy drugs, and may aid in predicting individual patient prognosis. Addition of carboplatin to neoadjuvant chemotherapy significantly improved DFS and OS in patients with TNBC but not in those with hormone receptor-positive, HER2-negative breast cancer.
- || epirubicin / Generic mfg., gemcitabine / Generic mfg.
Clinical, Journal: Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage. (Pubmed Central) - Dec 17, 2020
In the complete absence of BCG, consideration should be given to MMC with chemohyperthermia or electromotive drug administration where available or other intravesical chemotherapy. High-risk patients should be considered for cystectomy.
- || cyclophosphamide intravenous / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. (Pubmed Central) - Dec 17, 2020
High-risk patients should be considered for cystectomy. Despite similar long-term efficacy and safety profile, the higher breast conservation rate in the TC6 group suggests that preoperative chemotherapy without an anthracycline may benefit patients with HR-positive HER2-negative BC.
- || TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Clinical, Retrospective data, Journal: Effects of Different Chemoradiotherapy Regimens on Early Survival Outcomes in Patients with Locally Advanced Nasopharyngeal Carcinoma (Pubmed Central) - Dec 16, 2020
During concurrent radiotherapy, the incidence of grade 3-4 neutropenia in EPF combined with CNRT was significantly lower than that of DPF combined with CCRT (P=0.007). EPF combined with CNRT regimen is similar to DPF combined with CCRT regimen in survival outcomes, but the patients with T, N/N, and male nasopharyngeal carcinoma may benefit from EPF combined with CNRT regimen.
- | Brukinsa (zanubrutinib) / BeiGene
New P2 trial: Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Dec 16, 2020
P2, N=59, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Journal: Cooling-mediated protection from chemotherapy drug-induced cytotoxicity in human keratinocytes by inhibition of cellular drug uptake. (Pubmed Central) - Dec 15, 2020
We have also devised a flow cytometry-based methodology that permitted semi-quantitative analysis of differences in drug uptake, which demonstrated that cooling can reduce drug uptake by up to ~8-fold in comparison to normal/physiological temperature, an effect that was temperature-dependent. Our results provide evidence that attenuation of cellular drug uptake represents at least one of the mechanisms underpinning the ability of cooling to rescue human keratinocytes from chemotherapy drug-cytotoxicity, thus supporting the clinical efficacy of scalp cooling.
- Keytruda (pembrolizumab) / Merck (MSD), zolbetuximab (IMAB362) / Astellas
[VIRTUAL] Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_420;
P2
Pharmacokinetics, safety/tolerability, quality of life, and immunogenicity will be assessed. The study is currently recruiting pts.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_222;
Eligible patients were randomly assigned (1:1) to receive SHR-1210 (200mg, q2w) and apatinib (250mg, q.d.) for 12 cycles, or two times of standard HAI treatments (epirubicin 80-100mg or epirubicin 50mg+oxaliplatin 50mg). In HCC patients with high risk of recurrence after radical resection, SHR-1210 combined with apatinib was tolerable, and might offer a new promising choice superior to HAI for adjuvant therapy in HCC, further study is needed to reach the pre-defined primary endpoint.
- paclitaxel / Generic mfg.
[VIRTUAL] Selecting the optimal neoadjuvant treatment approach based on the risk of an involved surgical margin in locally advanced adenocarcinoma of the esophagus and esophagogastric junction. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_157;
Tailoring the neoadjuvant approach based on risk to CRM involvement appears feasible and warrants further investigation. Summary of key stage, pathology and survival data.
- | epirubicin / Generic mfg.
Biomarker, Journal, PARP Biomarker: PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. (Pubmed Central) - Dec 8, 2020
Moreover, tumor xenograft experiments further demonstrated that PARPBP was involved in breast cancer anthracycline resistance. Taken together, our results highlight that PARPBP is a prognostic marker and confers anthracycline resistance on breast cancer.
- || methotrexate IV / Generic mfg., fluorouracil topical / Generic mfg., paclitaxel / Generic mfg.
Clinical, Journal: A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma. (Pubmed Central) - Dec 3, 2020
Taxol was added in all node-positive cases, triple negative breast cancer (TNBC), and Her 2 positive cases...Preoperative chemotherapy downstages the primary tumors and axillary metastasis in patients with locally advanced breast carcinoma. Comparison of molecular subtypes with chemotherapy response is a better way to find out the predictors of response to chemotherapy.